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Abstract
Background: The treatment of intracranial aneurysms may be associated with cerebral ischemia. We hypothesize
that pre-interventional remote ischemic preconditioning (RIPC) reduces ischemic cerebral tissue damage in patients
undergoing elective intracranial aneurysm treatment.
Methods/Design: This study is a single-center, prospective, randomized, double-blind explorative trial. Patients with
an unruptured intracranial aneurysm admitted to Innsbruck Medical University Hospital for coiling or clipping will
be consecutively randomized to either the intervention group (= RIPC by inflating an upper extremity blood-
pressure cuff for 3 x 5 min to 200 mmHg) or the control group after induction of anesthesia. Participants will
be randomized 1:1 to either the preconditioning group or the sham group using a random allocation sequence and
block randomization. The precalculated sample size is n = 24 per group. The primary endpoint is the area-under-the-
curve concentration of serum biomarkers (S100B, NSE, GFAP, MMP9, MBP, and cellular microparticles) in the first five
days after treatment. Secondary endpoints are the number and volume of new ischemic lesions in magnetic resonance
imaging and clinical outcome evaluated with the National Institutes of Health Stroke Scale, the modified Rankin Scale,
and neuropsychological tests at six and twelve months. All outcome variables will be determined by observers blinded
to group allocation. This study was approved by the local institutional Ethics Committee (UN5164), version 3.0 of the
study protocol, dated 20 October 2013.
Discussion: This study uses the elective treatment of intracranial aneurysms as a paradigmatic situation to explore the
neuroprotective effects of RIPC. If effects are demonstrable in this pilot trial, a larger, prospective phase III trial will be
considered.
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Background
Treatment of unruptured intracranial aneurysms in-
volves maneuvers that may lead to cerebral ischemia in
up to 60 % of patients [1, 2]. Although the majority of is-
chemic lesions remain asymptomatic, they may contrib-
ute to subtle cognitive deficits after elective aneurysm
repair [2]. Ischemia-inducing events during aneurysm re-
pair include brain tissue retraction, deliberate temporary
cross-clipping or balloon occlusion of an afferent vessel
for proximal control or coil placement, accidental clip
occlusion of efferent vessels, thrombosis or thrombo-
embolism during treatment, and other no-flow phenom-
ena of unknown cause.
The effectiveness of interventions for protecting the
brain during aneurysm treatment is controversial, and
investigation of alternative techniques to increase the is-
chemic tolerance of the brain, not only during surgery,
is desirable [3–5]. Such interventions should be safe,
minimally invasive, controllable, cost-efficient, and,
when administered during neurosurgical or neuroradio-
logical interventions, practicable in the operating theater
and the interventional suite.
Preconditioning is one such potential technique to
achieve neuroprotection [6]. Preconditioning involves the
application of a stimulus near but below the threshold of
damage, aiming to protect an end organ from subsequent
injury [7, 8]. A variety of stimuli has been shown to induce
preconditioning [8]. In direct ischemic preconditioning
(DIPC), subthreshold ischemia is applied directly to the
perfusion territory that may later be exposed to more se-
vere ischemia. In remote ischemic preconditioning (RIPC),
subthreshold ischemia is induced in an organ or part of
the body that is remote from the target organ at risk. The
signal is thought to spread systemically by yet unidentified
mechanisms [8–12].
Clinical trials using preconditioning prior to interven-
tions that are associated with a high risk of intra-
interventional ischemia have been performed in a variety
of clinical disciplines [13-28].
Recently, the prevention of secondary damage associ-
ated with neural tissue injury itself has come into the
focus of preconditioning strategies [29–36]. For example,
Dupont-Hoougard and collaborators showed that RIPC,
applied during transport to hospital, results in increased
tissue survival after 1 month in patients undergoing
thrombolysis for acute stroke when baseline levels of hy-
poperfusion where taken into account [32].
The occurrence of delayed cerebral ischemia (DCI)
after subarachnoid hemorrhage (SAH) might be an ideal
setting for studying the effects of IPC [37, 38]. Gonzalez
and collaborators reported that patients undergoing
RIPC showed reduced middle cerebral artery mean vel-
ocities, a reduced lactate/pyruvate ratio, and reduced
glycerol levels. These effects lasted up to 2 days [39]. A
preexisting cerebrovascular steno-occlusive disease or a
preexisting infarction may also serve as a precondition-
ing stimulus that confers protection from radiologic
vasospasm after a subsequent subarachnoid hemorrhage
[40].
Techniques for ischemic preconditioning in associ-
ation with intracranial aneurysm treatment evaluated the
direct preconditioning effect of a two-minute vessel oc-
clusion on PtO2, PtCO2 and pHt in the brain tissue of
patients undergoing aneurysm clipping after aneurysmal
SAH. The decline in PtO2 and pHt was significantly
slower in the preconditioned group [41].
Two Cochrane reviews and at least one meta-analysis of
IPC are available. Gurusamy analyzed IPC in liver trans-
plantation. No evidence to support or refuse RIPC in donor
liver retrievals was observed for clinically important
markers (mortality, initial poor function, re-transplantation,
and primary graft non-function). Aspartate transaminase
levels as a biochemical marker of liver injury were different
only on the third postoperative day [42]. Similarly, a
Cochrane review of the effectiveness of IPC in vascular and
endovascular surgery revealed no statistically significant dif-
ference between the two groups for any outcome parameter
(including mortality) except reduced risk of myocardial in-
farction in the remote ischemic preconditioning group
(which was significant according to the fixed-effect model)
[43]. In a meta-analysis of 11 trials enrolling 1700+ patients
undergoing elective cardiac intervention for coronary artery
disease, RIPC significantly reduced the perioperative inci-
dence of myocardial infarction and the incidence of
contrast-induced acute kidney disease [44].
In summary, there is evidence from clinical trials that
preconditioning may work in humans. Unanswered
questions include type, timing and intensity of stimulus
and, concerning preconditioning for the prevention of
cerebral ischemia, outcome variables that have adequate
sensitivity and specificity and are practicable in the
clinical setting [37–39, 45, 46].
How can effects of ischemic preconditioning on cerebral
ischemia be detected?
(1)Serum biomarkers
Although proven serum biomarkers are available
for ischemia-related damage to cardiac, hepatic or
renal tissue [13, 17], clinical trials involving cere-
bral or spinal ischemic preconditioning are ham-
pered by the lack of reliable and specific
biomarkers for monitoring neuroprotective effects
[46, 47].
In stroke research, several biomarkers have been
investigated [48–50] and may therefore serve as
surrogate outcome variables in preconditioning
studies. Calcium-binding protein S100 beta
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(S100B) is a glial protein that belongs to a family
of calcium-mediated proteins named after their
solubility in ammonium sulfate [49]. It can be
found in astroglia, Schwann cells and in extra-
neural sources as in melanocytes, adipocytes and
chondrocytes [49]. Neuron-specific enolase (NSE)
is a glycolytic enzyme found mainly in the cyto-
plasm of neurons and cells of neuroendocrine ori-
gin, and in smaller concentrations in erythrocytes
and platelets [51]. NSE levels correlated with
stroke size in the majority of studies and high NSE
levels generally indicated more severe stroke, but
data are controversial.[51] S100B and NSE correl-
ate with cerebral ischemia lesion volume in com-
puted tomography (CT) and/or MR imaging [52, 53].
Glial fibrillary acidic protein (GFAP) is the
principal intermediate filament in mature
astrocytes [54]. In a small study investigating
biomarker detection of spinal cord damage during
descending aorta aneurysm repair, the GFAP levels
but not the S100B levels were associated with the
occurrence of neuronal damage [55]. Levels of
serum GFAP are higher in patients who
experience secondary ischemia after subarachnoid
hemorrhage [54]. GFAP levels and S100B levels
(but not NSE levels) after subarachnoid
hemorrhage correlated with the clinical condition
and the degree of hemorrhage of patients on
admission [56].
Myelin basic protein (MBP) is a major
constituent of central nervous myelin
synthesized by oligodendrocytes [49]. Whiteley
and collaborators reviewed 21 studies and found
S100B, NSE and MBP to be the only markers
tested having a specificity of > 90 % for
neuronal damage [48].
Metalloproteinases (MMPs) are secreted enzymes
that cleave protein substrates [57]. Excreted
MMPs are divided into several classes according
to their substrate. MMP9, a gelatinase first
described in neutrophils, plays a major role in the
degradation of basal membrane proteins and tight
junctions [57]. According to a review of 22 studies,
increased serum levels of MMP9 were significantly
correlated with infarct volume, stroke severity and
worse functional outcome in acute stroke patients
[58]. An MMP9 peak in serum is predictive for
delayed cerebral vasospasm (dCVS) days before
the onset of Doppler velocity changes or
neurological deterioration [59]. MMP9 was
observed to be significantly elevated in patients
with aneurysmal subarachnoid hemorrhage
(aSAH) who developed dCVS, as compared to
SAH patients without dCVS [60].
Microparticles (MPs) are blood-borne small mem-
brane fragments shed from apoptotic or otherwise
stimulated cells. They contain membrane compo-
nents and intracellular components that are in-
volved in cell signaling [61]. Elevated microparticle
levels are found in a variety of thromboembolic
diseases including acute coronary syndrome, myo-
cardial infarction, diabetes mellitus, venous
thromboembolism, atrial fibrillation, and ischemic
stroke [61–64]. Endothelial microparticles correl-
ate with clinical stroke severity and infarct volume
[65]. Data in patients after SAH are controversial.
In one study, the levels of endothelial microparti-
cles were higher in patients experiencing vaso-
spasm after SAH [66]. In another study, levels of
microparticle subtypes associated with thrombosis
and endothelial dysfunction were lower in patients
with infarcts after SAH [67]. In RIPC, microparti-
cles may play a special role as biological messen-
gers. In an animal model, Giricz and collaborators
were recently able to demonstrate that protection
of the heart by RIPC is mediated by extracellular
vesicles [68].
In summary, none of the investigated biomarkers
including those mentioned above, possess the
specificity and sensitivity of biomarkers available
to study, for example, cardiac ischemia. At
present, use of a panel of biomarkers,
determination of their concentration curve over
time after an ischemic event and storage of serum
probes for future determination of hitherto
unknown biomarkers appear to be the most
appropriate strategies in an exploratory study of
central nervous IPC [46, 69].
(2)Neuroimaging
Diffusion-weighted imaging (DWI) and fluid-
attenuated inversion recovery (FLAIR) are able to
demonstrate new ischemic lesions with high sensi-
tivity and specificity [70–72]. Multimodal MRI is
included in standard protocols for stroke imaging
[73]. The technique for comparing pre-
interventional MRI to post-interventional MRI for
the number and volume of new lesions in
diffusion-weighted MRI and fluid-attenuated in-
version recovery imaging was used successfully in
a recent neuroprotective trial involving patients
undergoing endovascular aneurysm repair [1].
Therefore, this technique is considered adequate
for studying the effects of neuro-intervention and
alterations due to IPC.
(3)Clinical examination
Clinical central nervous effects of IPC can be
masked by confounding factors. Nevertheless,
clinical effects have been demonstrated in patients
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suffering a stroke after preceding TIA [33] and in
a recent large trial involving stroke patients
undergoing RIPC during the prehospital phase.
Although this was not the primary nor the
secondary outcome in this study, patients in the
treatment group presented with a lower NIHSS on
admission [32]. Since improvement of the clinical
outcome will remain the ultimate goal of all
procedures aimed at preventing ischemic brain
damage, clinical outcome variables should be
investigated in a trial involving IPC.
Why investigate RIPC in patients with an unruptured
intracranial aneurysm?
Treatment of unruptured intracranial aneurysms under
general anesthesia is a highly standardized clinical situ-
ation. In this situation, (1) the incidence of clinically si-
lent ischemia is high (as high as 60 % in patients
undergoing endovascular procedures [1, 74]), (2) no pre-
vious ischemic damage has occurred (and a baseline for
biomarker determination can be established beforehand),
and (3) the preconditioning stimulus can be adminis-
tered at a pre-specified moment prior to occurrence of
the real damage. Aneurysm treatment may therefore
present some essential features needed to study the in-
duction of ischemic tolerance in the brain under clinical
conditions despite all problems associated with the de-
termination of valid study endpoints [37, 45, 75, 76].
Why include two different procedures in the study protocol?
We included both procedures - microsurgical clipping
and endovascular coil occlusion of intracranial aneu-
rysms - because both may induce focal cerebral ischemia
(ischemia to one defined cerebral vascular territory) and
because both may lead to local endothelial damage. Both
procedures carry a comparable risk to induce focal cere-
bral ischemia.
The difference is that, in endovascular procedures, the
source of ischemia is inside the vessel and in direct con-
tact with the endothelium and the bloodstream, whereas
in microsurgical clipping, the ischemia-inducing agent is
outside the vessel lumen. This might be a drawback in
the study design but could also increase the external val-
idity of this study. Other possible technical confounders
in a study of this type that defeat standardization include
but are not limited to (1) a different duration of vessel
occlusion between the study individuals, (2) a lack of
possibility to differentiate between complete and incom-
plete vessel occlusion, (3) the impossibility to control for
collateralization of the occluded vascular territory, and
(4) the fact that some patients will undergo repetitive oc-
clusion periods and others a singular occlusive period as
dictated by clinical necessity.
The goal of the RIPAT study is to investigate whether
remote ischemic preconditioning during the elective
treatment of intracranial aneurysms reduces the occur-
rence of ischemic damage as measured by serum bio-
marker determination, neuroimaging, and clinical, as
well as neuropsychological, examination.
Methods/design
Study setting
The trial will be conducted at Innsbruck Medical University
Hospital, an academic tertiary care center that also serves
as the referral center for all patients with intracranial vascu-
lar pathologies requiring neuro-intervention in the western
part of Austria.
Trial design
RIPAT is a randomized, prospective, controlled, double-
blind, exploratory clinical trial.
Patients
All patients admitted to the Departments of Neurosurgery
or Neurology with one or more unruptured intracranial
aneurysm(s) will be discussed by an interdisciplinary vas-
cular board consisting of neurosurgeons, neuroradiolo-
gists, and neurologists and considered for study inclusion
if aneurysm treatment is indicated by board decision.
Patients with asymptomatic intracranial aneurysm(s)
are eligible for the study if they (1) are aged 18 or older,
(2) agree to undergo endovascular coiling or surgical
clipping, and (3) give their consent to the study. Exclu-
sion criteria are as follows: (1) presence of clinical or
radiological signs of subarachnoid hemorrhage; (2) my-
cotic or dissecting morphology of the aneurysm(s); (3)
preplanned vessel sacrifice as the aneurysm treatment
modality of choice; (4) history of stroke or TIA within
the last 6 months; (5) signs or symptoms of peripheral
vascular disease; (6) previous serious cerebral diseases
that would preclude protocol completion or MRI ana-
lysis of minor strokes; (7) any contraindications against
MRI scan; (8) language barriers that would prevent com-
pletion of the neuropsychological tests; (9) drugs, life-
style factors, and systemic illness that interfere with
biomarker determination and (10) pregnancy.
Procedures
Figure 1 depicts the structure of the trial.
Remote ischemic preconditioning (RIPC) and sham
preconditioning (SPC)
Study patients will be randomly assigned to either the
preconditioning group (Group A, treatment group) or
the control group (Group B, sham preconditioning) on
opening a sealed envelope containing the group assigna-
tion after anesthesia is induced in the induction room.
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In both RIPC and SPC, a standard blood pressure cuff is
fixed on the patient’s upper arm. Care will be taken to
ensure that the blood-pressure cuff is adequate to ac-
commodate the patient’s arm [77]. In Group A, RIPC
consists of cuff inflation to 200 mmHg for 3 x 5 min al-
ternating with 5 min of intermittent reperfusion by
complete cuff deflation. In Group B, maximum cuff
inflation pressure is limited to 10 mmHg for 3 x 5 min
alternating with 5 min of complete cuff deflation.
RIPC and SPC will be performed by the anesthesiologist
aided by a second, unblinded member of the study team
after the induction of general anesthesia and prior to
definitive patient positioning for the intervention. These
two members of the team are not involved in the intra-
interventional decisions concerning deliberate ischemia
and are blinded for outcome analysis. Standard operation
procedures (SOP) describing the preconditioning proced-
ure are available to all investigators (see Additional file 1:
Supplementary material). A written checklist must be
completed by those performing the preconditioning to
ensure protocol adherence (see Additional file 1:
Supplementary material).
Adverse events or unintended effects of the trial inter-
vention will be noted in the preconditioning protocol
Fig. 1 Flowchart of the trial (MRI = magnetic resonance imaging)
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and communicated to those performing the subsequent
aneurysm treatment. The decision to abort the aneurysm
treatment procedure in such a situation will be made by
the surgeon or the endovascular therapist after confer-
ring with the principal investigator. Patients with a com-
plication will be managed in a manner appropriate to
the situation and informed thereof after recovery from
anesthesia.
Aneurysm treatment
Treatment of intracranial aneurysms will consist of ei-
ther microsurgical clipping or endovascular coiling
under general anesthesia following standard methods.
All events that could possibly be associated with ische-
mia, including a drop or deliberate reduction in the sys-
temic blood pressure of more than 20 % of the prior
systolic blood pressure lasting more than 3 min and
every deliberate or unintentional vessel occlusion during
the procedure will be recorded by the anesthesiologist.
All injuries and unintended effects associated with the
preconditioning procedure or the aneurysm treatment
will be registered.
The anesthetic protocol is not prespecified. We expect
that the majority of patients will receive total intraven-
ous anesthesia (TIVA) that includes propofol because
this is the standard anesthesiologic regimen in our
neurosurgical patients. However, the anesthesiologist is
free to use the protocol that he/she thinks is the most
appropriate. Different interventions will not require dif-
ferent anesthetic protocols.
Biomarker analysis
Blood samples for biomarker analysis will be drawn by the
nursing staff at pre-specified time points as described
below. The first sample will be taken within 24 h preced-
ing intervention, providing an individual baseline for each
patient. Further blood samples will be taken immediately
prior to the preconditioning procedures, after the precon-
ditioning and prior to the start of the aneurysm treatment,
as well as at 0, 3, 6 and 12 h and daily thereafter for 5 days
after completion of aneurysm treatment. Serum bio-
markers will be determined at the Central Institute for
Medical and Chemical Laboratory Diagnostics of the
Medical University of Innsbruck. NSE will be measured by
means of an electrochemical luminescence immunoassay
based on monoclonal antibodies, detecting the γ subunit
of NSE (Elecsys, Roche Diagnostics GmbH, Mannheim,
Germany). S100B will be determined by an electrochem-
ical luminescence immunoassay, using monoclonal
antibodies specifically targeted on the astrocyte-specific β-
chain of the S100 dimer (Elecsys, Roche Diagnostics
GmbH, Mannheim, Germany). MMP9 will be quantified
by an MMP9 sandwich enzyme immunoassay (R&D
Systems, Minneapolis, MN, USA) that detects the 92 kDa
proactive and the 82 kDa active forms, but not the 65 kDa
form with monoclonal antibodies. GFAP and MBP will be
measured by sandwich enzyme immunoassays based on
polyclonal antibodies (GFAP: biovendor, Heidelberg,
Germany; MBP: USCN Life Science, Wuhan, China). Cel-
lular microparticles will be analyzed using fluorescence-
activated cell sorting (FACS) from plasma in the Research
Laboratory of the Department of Neurology using the
methodology described previously by Lackner [66]. Serum
samples will be stored at –80 °C for future analysis in an-
cillary studies at the Central Institute for Medical and
Chemical Laboratory Diagnostics.
Neuroimaging
All patients undergo a baseline MRI scan within 48 h pre-
ceding aneurysm treatment. In all patients, a post-
interventional MRI scan will be performed 12 to 48 h after
termination of the aneurysm treatment. All imaging will be
done in the Department of Neuroradiology of the Medical
University of Innsbruck. Study imaging protocol includes
an axial FLAIR sequence with 3-mm slice thickness, an
axial DWI sequence with 2-mm slice thickness and an
axial T1-weighted 3 days magnetization-prepared rapid
gradient echo (MPRAGE) sequence with 1-mm slice thick-
ness. Pre-interventional and post-interventional MR se-
quences will be compared. The presence and age of
ischemic lesions in the pre-interventional MRI will be
identified, apparent diffusion coefficient (ADC) and frac-
tional anisotropy (FA) values will be measured with region
of interest (ROI) technique in different brain regions of
both hemispheres (frontal, parietal, temporal occipital
white matter, putamen, internal capsule, and pons) and
brain volume will be determined by voxel-based morph-
ometry. In the post-interventional images, new ischemic le-
sions will additionally be detected. Number (in absolute
numbers) and volume (in mm3) of the new ischemic le-
sions will be calculated, and the ADC/FA values within the
lesions will be measured. Imaging data will be independ-
ently assessed by two experienced consultant neuroradiolo-
gists blinded to the intervention. Discrepancies in image
interpretation will be solved by consensus. All values will
be examined for normality and appropriate statistical
methods will be used. Average time-to-post-interventional
MRI for both groups will be reported.
Follow-up
Follow-up examinations are scheduled at 6 and 12 months
after aneurysm treatment and include clinical assessment,
MRI scan, and neuropsychological examination. Although
not specifically excluded from the study, patients who
seem unable to comply with follow-up will be included
only after being interviewed about their willingness to
participate also in the follow-up examinations.
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Clinical evaluation
Clinical outcome after 6 and 12 months will be assessed
by a neurologist blinded to the preconditioning procedure
using the National Institutes of Health Stroke Scale
(NIHSS) (http://www.ninds.nih.gov/doctors/stroke_scale_-
training.htm, accessed 8 January 2015) and the modified
Rankin Scale (mRS) [77]. Clinically apparent deficits or
unintended effects will be noted. The examination will





All patients undergo standardized neuropsychological
examination in the week before treatment and at the 6-
and 12-month follow-ups in the rooms of the neuropsycho-
logical laboratory of the Department of Neurology. Testing
will be performed by an experienced neuropsychologist
blinded to the preconditioning procedure. The test battery
includes the Verbal Learning Memory Test, [79] the Digit
Span Test from the Wechsler Memory Scale (WMS), [80]
Trial Making Test A/B, [81] Regensburg Word Fluency
Test, [82] the Go/No-go Task 2 stimuli 1 target from the
Test of Attentional Performance (TAP) [83] and the
Hospital Anxiety and Depression Scale (HADS-D) [84].
Statistics
Blinding
Study patients, as well as all members of the medical,
nursing and scientific staff involved in study patient
treatment, will remain blinded to patient group alloca-
tion. All data collected for the trial will be collected by
members of the research team who do not know the
treatment allocation. The anesthesiologists, including
ML and two neurosurgeons (MM and DP), are respon-
sible for execution of the RIPC procedure and therefore
will be the only unblinded study members and will not
be involved in the study patient treatment, outcome ana-
lysis or data analysis.
RIPC takes place in an ancillary room of the operating
theater or the neurointerventional suite, separated from
the main rooms by soundproof doors fitted with small
windows. The patient is therefore shielded almost com-
pletely from occasional onlookers. The interventional
team (surgeons or endovascular therapists) is summoned
to enter this room and proceed with patient positioning
for intervention after completion of the preconditioning
procedure.
Randomization
The Center for Statistical Consulting and Continuing
Education (CSCCE) at UMIT (University for Health
Sciences, Medical Informatics and Technology) gener-
ated the random allocation sequence using the PLAN
procedure in the SAS statistical package V.9.1. Partici-
pants were randomized 1:1 to either the preconditioning
group or the sham group using block randomization
with a block size of four at a time and a random-block
sequence. Assignment of the study subjects was docu-
mented in a randomization schedule. Sequentially num-
bered sealed opaque envelopes containing group
allocation for each patient were prepared using the ran-
dom allocation sequence by a statistician not involved in
patient treatment. Envelopes will be opened by one of
the unblinded members of the study group (see above)
after induction of anesthesia.
Statistical analysis
Statistical analysis will be performed by an independent
external statistician (RMG). This study is designed as an
explorative study to provide data for future confirmatory
studies. The main outcome variable (area under the
curve, AUC) for each biomarker will be analyzed using
intra-operative ischemia as the only explanatory variable
in the two groups. No corrections will be made for
multiplicity. A difference of ≥ 2 standard deviations (SD)
in the main outcome variable is considered to be a sta-
tistically relevant effect. The alpha level is set at 0.05 %.
The 95 % confidence intervals for the differences will be
calculated.
No a priori empirical evidence suggests which of the six
chosen biomarkers would be the ideal single primary out-
come, but to define the sample size, we allocated the AUC
of S100 as the primary outcome. Power analysis aiming to
detect a difference of more than two SD in the primary
outcome between the groups would require a sample size
of n = 16σ2/d2 for a two-sided α = 0.05 and 1-β = 0.8 [85].
N = 4 patients per group would permit a difference of ≥ 2
SD in serum biomarker levels to be detected in the study
population. Assuming that only one in five patients will
sustain cerebral ischemia during aneurysm treatment, this
would require a sample of n = 20 patients per group. Add-
itional 20 % (n = 4 patients) per group will be included for
unexpected dropouts, unexpected low rates of intra-
interventional ischemia or unexpected loss to follow-up.
This would require a total study population of n = 48
patients (n = 24 per group).
All statistical analysis will be performed on an intention-
to-treat basis and per protocol. Standard methods of ex-
ploratory data analysis will be used for group comparison.
Quantitative parameters will be tested for normality and
compared using the t test or compared with the Mann–
Whitney U test for non-normally distributed data. Qualita-
tive parameters will be compared using the chi-squared
test or Fisher’s test. Group differences for the main out-
come variable will be compared using the two-sided t test
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for independent groups or the Mann–Whitney U test, as
appropriate. Secondary outcome parameters will be com-
pared using the Mann–Whitney U test for quantitative
data and the chi-squared or Fisher's test for dichotomized
outcome data.
Preplanned subgroup analyses include an analysis
stratified by aneurysm treatment technique (microsurgi-
cal or endovascular) and by anesthetic regimen (with or
without propofol).
Missing data for biomarker serum values (for example,
due to hemolytic probes) will be handled using a statistical
model and the maximum likelihood method, in which es-
timates and standard errors are based on the likelihood
function given in the observed data. Missing imaging data
(for example, inability to investigate by MRI during the
first 2 postoperative days) will be replaced by calculating
the number and volume of areas assumed to be due to is-
chemia on the basis of CT scans (if available)
The SAS software package V9.1 will be used for statis-
tical analysis.
Ethical considerations
The study complies with the Helsinki Declaration [86]
and was approved by the local institutional Ethics Com-
mittee of the Medical University of Innsbruck (Ethik-
kommission der Medizinischen Universität Innsbruck,
Geschäftsstelle, Innrain 43, 1.Stock, A-6020 Innsbruck)
(UN5164) in Version 3.0 of the study protocol, dated
October 20 2013. An amendment of the study protocol
was approved by the same institution on April 24, 2015
(UN 5164, 327/4.18, 348/5.7). The present paper in-
cludes all changes contained in this amendment. Future
amendments, if necessary, will be available through the
trial registration database (see below).
Informed consent from potential trial participants will
be obtained either by the principal investigator (MO) or
by the collaborators CU, RB, RH and ES after the board’s
recommendation for aneurysm treatment. The model
consent form V.3.1 dated October 28, 2013 is available
under Additional file 1: Supplementary materials.
Patients may discontinue their participation in the
study at any time upon request.
The study is registered with www.clinicaltrials.gov (regis-
tration ID: NCT02162654) and with the Clinical Trial Cen-
ter of the Medical University of Innsbruck (http://ctc.tirol-
kliniken.at/page.cfm?vpath=oeffentliche&action=viewde-
tail&studie=5430) (registration ID: 20131101–823).
Safety of RIPC
With RIPC, the intentional exposure of ischemia-
sensitive organs - such as the brain - is avoided by apply-
ing stimuli to more ischemia-tolerant tissues like skeletal
muscle. Obviously, direct vessel manipulation for intro-
duction of the preconditioning stimulus is also avoided.
Although negative effects of IPC cannot be fully ex-
cluded, up to now neither experimental nor translational
data have documented any negative effects. The IPC
protocol that will be employed in our trial has been used
in other clinical trials without known adverse events. A
phase Ib trial in awake patients investigating the feasibil-
ity and safety of IPC using RIPC in the leg did not dem-
onstrate any adverse events associated with RIPC [87]. A
discomfort questionnaire was completed by 80 study pa-
tients undergoing preclinical RIPC in the arm for sus-
pected cerebral ischemia. None reported any significant
discomfort [32].
However, repetitive ischemia in a limb of patients with
signs of occlusive peripheral vascular disease may cause
additional damage to this limb. Therefore, these patients
are excluded from study participation (see exclusion
criteria).
Subtle changes in coagulation time (PT and INR, not
PTT) were observed in patients undergoing at least four
cycles of RIPC after SAH. No hemorrhagic complica-
tions were observed in this study [88]. The study was
published after enrollment of our first patients. A debate
ensued in the steering committee concerning whether
patients undergoing stent-assisted coiling (and therefore
requiring acetylsalicylic acid and clopidogrel preloading)
would be exposed to an increased risk for hemorrhagic
complications. One potential study patient was not in-
cluded for these reasons. After thorough discussion, we
concluded from the available evidence that our RIPC
scheme (three cycles of upper arm ischemia with the pa-
tient under general anesthesia) does not raise safety con-
cerns for the subsequent aneurysm treatment procedure
(including stent-assisted coiling).
Other potential risks associated with participation in this
study
Study inclusion requires anesthesia to be prolonged for
approximately 30 min. During this time, the patient is
fully monitored and under the supervision of a senior
anesthesiologist.
Biomarker determinations will not interfere with the
clinical routine in any way. Patients undergoing aneurysm
treatment are assumed to undergo preoperative and daily
blood sampling for routine monitoring purposes there-
after for at least 5 postoperative days at regular intervals
and as deemed necessary thereafter. Participation in the
study requires the additional removal of a small amount
of blood at predetermined intervals without separate
venipuncture. All patients have central venous lines in
place according to standard operating procedures. Blood
removal is not considered a risk. A separate venipuncture,
if necessary in an exceptional situation, can cause discom-
fort if the patient is awake.
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All patients subjected to aneurysm treatment undergo
imaging prior to treatment and after the procedure.
Study participation requires an MRI in all patients prior
to treatment, within 48 h after treatment, at 6 months
and at 1 year. Thus, patients who normally would not
undergo MRI examination at these time points, that is,
in whom ischemia is not suspected on clinical or im-
aging (CT) grounds, will also undergo MRI. MRI does
not involve radiation. Patients not appropriate for MRI
investigation will not be included in the study (see exclu-
sion criteria). In artificially ventilated patients, MRI
examination will be supervised by an experienced
anesthesiologist. The Clinical Departments of Neurora-
diology and Anesthesiology of the Medical University of
Innsbruck have long-standing experience with MRI ex-
aminations in severely ill or intubated neurological
patients. Examination of intubated patients is possible
24/7.
Neuropsychological testing will be performed prior to
the intervention and at 6 and 12 months during the
regular outpatient visits. This additional testing will pro-
long these visits for approximately 2 hours.
All patients in our departments undergo regular
follow-up visits at 4 weeks, 6 months and 1 year after
treatment of an intracranial aneurysm. Data concerning
functional outcome will therefore be recorded as part of
the routine clinical documentation. No additional visits
to the outpatient department for study purposes will be
necessary. Study participants not willing or able to
present for the follow-up visit, for whatever reason, will
be contacted by telephone and interviewed using the
structured questionnaire published by Bruno [89].
Adverse events
Events considered adverse events associated with RIPC
therefore include intra-interventional or post-interventional
changes in coagulation parameters not commonly seen
during neurosurgical or neurointerventional procedures.
Severe adverse events include (1) all events that are rarely
observed during routine treatment of intracranial aneu-
rysms and that cause a new neurological deficit or require
re-intervention, (2) all hemorrhagic complications causing
a new neurological deficit, and (3) every ischemic damage
to a limb that underwent RIPC.
Data handling and data safety
A patient identification list with information about all
study patients will be authored by the investigators. This
list will contain every patient’s full name, ID number,
date of birth, contact address, name and contact infor-
mation of the family doctor, date of inclusion in the
study, date of termination of study participation and (if
applicable) date and reason for preliminary exclusion
from the study. A patient allocation list showing the
patients’ group assignment will be administered by the
Clinical Department of Anesthesiology (ML).
All data will be pseudonymized as soon as clinically
reasonable. Data entry in an electronic database (SPSS
spreadsheet) will be performed in pseudonymized form
by ST and checked by a second operator. Data will be
stored in a database hosted by the IT Services of Inns-
bruck Medical University Hospital that is accessible only
within the Clinical Department of Neurosurgery. Backup
storage of this database is performed automatically every
24 h. Data analysis and dissemination will be performed
using anonymous data exclusively.
Confidentiality of patient data is assured by restricted
access to the storage device granted to authorized inves-
tigators only. Data entry will be performed, dated and
signed by authorized investigators only. Authorized in-
vestigators are identified in a signature log, which will be
stored in the Investigator’s Site File. Case Report Forms
(CRF) and coding information will be stored by the
principle investigator after data input.
Methods for ensuring quality control and adherence to the
study plan
The Department of Neurosurgery has installed a Data
Monitoring Committee that meets every week to discuss
ongoing studies. All patients who are potential candi-
dates for study inclusion and all RIPAT study partici-
pants will be reviewed in this meeting. Additionally, all
RIPAT investigators meet at least twice a year to discuss
pertinent study progress issues. Prior to study initiation
nursing staff was instructed about goals and details of
the study. Written SOPs that accompany the various
steps of the study (patient screening, preconditioning
procedure, taking of blood samples) were issued and
made available to all staff.
Dissemination
The study protocol following SPIRIT guidelines [90, 91]
will be published in a peer-reviewed journal with open
access. A report drafted by the principal investigator and
authored by all investigators after completion of the
study will be submitted for peer-reviewed publication in
two parts. The first part, which is due 3 months after
the end of patient recruitment, will report on the effects
of RIPC on the primary outcome (biomarker concentra-
tion) and on short-term neuroimaging changes. A sec-
ond report concerning clinical outcome will be filed
after follow-up of the entire study cohort has been com-
pleted. All reports will be linked by citing the registra-
tion details. The reports will be prepared according to
CONSORT guidelines and its extension to non-
pharmaceutical interventions" [92] and comply with the
ICH GCP Guidelines for Structure and Content of
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Clinical Study Reports [93]. The principal investigator
will have unrestricted access to the final dataset.
Discussion
This study uses the elective treatment of intracranial an-
eurysms as a paradigmatic situation to explore the neu-
roprotective effects of remote ischemic preconditioning.
In this setting, ischemia as visualized by neuroimaging
does occur, but is usually not clinically relevant. Never-
theless, serum biomarkers and/or advanced MRI tech-
niques may be able to detect significant group
differences between patients who underwent remote is-
chemic preconditioning and those who did not. In this
case, any of these biomarkers may be a candidate as a
secondary outcome parameter for future exploration in
adequately powered phase III trials aimed at demonstrat-
ing a clinically relevant difference as the primary out-
come. The primary outcome in such a trial could be the
rate of cerebral events assessed within 30 days after
randomization. These events comprise death or any new
neurological deficit (whether temporary or permanent)
attributable to an ischemic lesion detected by neuroim-
aging. We estimate that, in the setting of a multicenter
study involving different institutions and different inter-
ventionalists, the rate of such events is 5 % in this pa-
tient population and that a reduction of this rate by
50 % would be clinically worthwhile.
In case any primary outcome parameter of the RIPAT
trial does not show a statistically significant difference
between the treatment and intervention group, the plan-
ning of future trials using ischemic preconditioning in
this patient group will be based on the analysis of full re-
sults including all clinical, imaging, and neuropsycho-
logical data.
The study has limitations. First, this is a single-center
trial. Second, serum biomarkers in the field of cerebral
ischemia may lack the sensitivity and specificity of bio-
markers used to monitor cardiac, renal or hepatic ische-
mia. Third, power analysis for the study is based on the
assumption that the determination of a continuous vari-
able, namely the area under the curve of a biomarker, is
able to show differences between the treatment and con-
trol group. Effects detected by serum biomarkers might
be so small that this exploratory study will be found to
be underpowered. Fourth, although we use the upper ex-
tremity and an established protocol to induce remote is-
chemic preconditioning, the ideal place and timing for
providing protective effects is actually unknown. Fifth,
we appreciate that a surgical intervention under total
intravenous anesthesia that uses propofol is associated
with a large number of stimuli that may also have
neuro-altering effects. This may lead to bias. Sixth, two
procedures are used to induce focal cerebral ischemia,
and although both are believed to be associated with a
comparable risk to induce focal cerebral ischemia, the
risks may be comparable but not identical.
The strengths of this study are, first, that it explores is-
chemic preconditioning in a highly standardized clinical
situation, namely the elective treatment of an unrup-
tured intracranial aneurysm. In this situation, precondi-
tioning stimulus and ischemic stimulus are time-locked
in a highly standardized fashion. Second, we employ a
simple, clinically applicable preconditioning technique
that was used successfully in other clinical trials investi-
gating end-organ ischemia. If this technique is effective,
it may be applicable in many other areas of medicine.
Third, the serum biomarkers used to determine the pri-
mary outcome are biomarkers that are widely available
and that have been used successfully in other clinical tri-
als of cerebral ischemia research.
The results of this trial will not provide a definitive an-
swer to the question of whether remote preconditioning
is useful for protecting the brain from ischemia, but are
expected to provide data essential to designing larger
multicenter phase III trials.
Trial status
The first patient was enrolled in November 2013. At the
time of manuscript submission, enrollment of partici-
pants continues.
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